Contact
searchSearch
HMP Global

Migraine

Featured Article

Fenty
Videos
Exploring the Impact of Early CGRP Therapy Initiation on Migraine Treatment
02/10/2025
In an interview with a guest expert, learn about the history and current use of CGRP therapies for patients with migraines.
In an interview with a guest expert, learn about the history and current use of CGRP therapies for patients with migraines.
In an interview with a guest...
02/10/2025
First Report Managed Care
LMW
Podcasts
Understanding Early CGRP Therapy Initiation in Migraine Treatment
11/22/2024
Lucy Myint-Wilks, BMBS, MSc, MRCS
Explore the latest advancements in migraine research, treatment options, cost-effectiveness, and the role of technology in managing migraines in this informative episode.
Explore the latest advancements in migraine research, treatment options, cost-effectiveness, and the role of technology in managing migraines in this informative episode.
Explore the latest advancements...
11/22/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Headshot of Ed Pezalla, Enlightenment Bioconsult, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
What Payers Should Know About Managing Chronic vs Episodic Migraine Costs
12/05/2022
Maria Asimopoulos
Edmund Pezalla, MD, MPH, chief executive officer, Enlightenment Bioconsult, LLC, reviews the costs associated with chronic vs episodic migraine and what payers should keep top of mind when managing these patients.
Edmund Pezalla, MD, MPH, chief executive officer, Enlightenment Bioconsult, LLC, reviews the costs associated with chronic vs episodic migraine and what payers should keep top of mind when managing these patients.
Edmund Pezalla, MD, MPH, chief...
12/05/2022
First Report Managed Care
News
What Stakeholders Value in Migraine Medicines
12/16/2020
“Value‐based contracts linking medication payments to predefined performance metrics aim to promote value through aligned incentives and shared risk between manufacturers and payers,” researchers wrote.
“Value‐based contracts linking medication payments to predefined performance metrics aim to promote value through aligned incentives and shared risk between manufacturers and payers,” researchers wrote.
“Value‐based contracts linking...
12/16/2020
First Report Managed Care
News
Eli Lilly Prices New Class of Migraine Treatment
02/03/2020
Reyvow (lasmiditan), a first-of-its-kind acute migraine treatment from Eli Lilly, was recently priced and will be available at pharmacies this week.
Reyvow (lasmiditan), a first-of-its-kind acute migraine treatment from Eli Lilly, was recently priced and will be available at pharmacies this week.
Reyvow (lasmiditan), a...
02/03/2020
First Report Managed Care
News
Understanding Why Opioid Use is High Among People With Migraine
04/09/2019
A team of researchers recently found that opioid use is common among migraine patients using prescription medication, and they sought to identify variables associated with opioid use among these patients.
A team of researchers recently found that opioid use is common among migraine patients using prescription medication, and they sought to identify variables associated with opioid use among these patients.
A team of researchers recently...
04/09/2019
First Report Managed Care
News
Patient Reported Outcomes Similarly Impacted By Migraine Treatments
04/04/2019
According to recent study findings, patient reported outcomes were no different among patients treated with calcitonin gene-related peptide antagonists or onabotulinumtoxinA for the indication of chronic migraine prophylaxis.
According to recent study findings, patient reported outcomes were no different among patients treated with calcitonin gene-related peptide antagonists or onabotulinumtoxinA for the indication of chronic migraine prophylaxis.
According to recent study...
04/04/2019
First Report Managed Care
News
Decreasing Number of Migraine Days With Aerobic Exercise
03/18/2019
Aerobic exercise appears to reduce the number of days patients experience migraine, according to a systematic literature review and meta-analysis published in The Journal of Headache Pain.
Aerobic exercise appears to reduce the number of days patients experience migraine, according to a systematic literature review and meta-analysis published in The Journal of Headache Pain.
Aerobic exercise appears to...
03/18/2019
First Report Managed Care
News
New Migraine Biologics Seek to Win Over Patients Before Insurers
03/04/2019
The new class of calcitonin gene-related peptide inhibitors for migraine relief appear to represent a major evolution in migraine therapy, but high costs may hinder patient access to the biologics, according to a recent paper.
The new class of calcitonin gene-related peptide inhibitors for migraine relief appear to represent a major evolution in migraine therapy, but high costs may hinder patient access to the biologics, according to a recent paper.
The new class of calcitonin...
03/04/2019
First Report Managed Care
News
Migraine Imposes High Economic Burden
02/15/2019
Direct, indirect, and societal costs were all significantly higher among patients with migraine compared with patients without migraine, according to a recent study in the Journal of Occupational and Environmental Medicine.
Direct, indirect, and societal costs were all significantly higher among patients with migraine compared with patients without migraine, according to a recent study in the Journal of Occupational and Environmental Medicine.
Direct, indirect, and societal...
02/15/2019
First Report Managed Care

Newsfeed

News
Semaglutide and Tirzepatide Demonstrate Long-Term Cost-Effectiveness Among Patients With MASH
10/13/2026
Rebecca Amrick
In a cost-effective analysis of pharmacotherapies, semaglutide and tirzepatide demonstrated better cost-effectiveness than standard of care among patients with metabolic dysfunction‐associated steatohepatitis (MASH).
In a cost-effective analysis of pharmacotherapies, semaglutide and tirzepatide demonstrated better cost-effectiveness than standard of care among patients with metabolic dysfunction‐associated steatohepatitis (MASH).
In a cost-effective analysis of...
10/13/2026
First Report Managed Care
News
Axi-Cel and Tisa-Cel Show Comparable Adjusted Efficacy in Relapsed or Refractory Follicular Lymphoma
10/13/2026
Rebecca Amrick
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with relapsed or refractory follicular lymphoma receiving chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel) was associated with improved effectiveness and higher toxicity compared to...
In an analysis of patients with...
10/13/2026
First Report Managed Care
News
Asciminib Associated With Durable Molecular Responses Among Patients With CML-CP
10/09/2026
Rebecca Amrick
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib 200 mg twice daily demonstrated significant efficacy and manageable toxicity among patients with T315I-mutated chronic myeloid leukemia in chronic phase (CML-CP).
Researchers found that asciminib...
10/09/2026
First Report Managed Care
Behind the Bill
New Federal Rule Strengthens Health Insurer Price Transparency Standards
10/09/2026
Hannah Musick
Federal regulators have finalized new health insurance price transparency requirements aimed at improving pricing disclosures, strengthening consumer access to cost information, and streamlining reporting obligations for health plans and...
Federal regulators have finalized new health insurance price transparency requirements aimed at improving pricing disclosures, strengthening consumer access to cost information, and streamlining reporting obligations for health plans and...
Federal regulators have...
10/09/2026
First Report Managed Care
News
US Study Identifies Survival Trends and Disparities Across Myeloproliferative Neoplasms
10/09/2026
Hannah Musick
A US population-based study of more than 63 000 patients with myeloproliferative neoplasms identified improved survival in primary myelofibrosis alongside persistent differences in incidence and survival across disease subtypes, age groups,...
A US population-based study of more than 63 000 patients with myeloproliferative neoplasms identified improved survival in primary myelofibrosis alongside persistent differences in incidence and survival across disease subtypes, age groups,...
A US population-based study of...
10/09/2026
First Report Managed Care
News
Mosunetuzumab Associated With Improved Survival Among Patients With Relapsed or Refractory FL
10/09/2026
Rebecca Amrick
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that mosunetuzumab was associated with high response rates and manageable safety among patients with relapsed or refractory follicular lymphoma (FL), even those who do not qualify for clinical trials.
Researchers found that...
10/09/2026
First Report Managed Care
News
Ruxolitinib Cream Improves Moderate Atopic Dermatitis After Prior Topical Treatment Failure
10/08/2026
Hannah Musick
In the phase 3 TRuE-AD4 trial, ruxolitinib cream significantly improved disease severity, itch, and quality of life among adults with moderate atopic dermatitis who had not responded adequately to conventional topical therapies, potentially...
In the phase 3 TRuE-AD4 trial, ruxolitinib cream significantly improved disease severity, itch, and quality of life among adults with moderate atopic dermatitis who had not responded adequately to conventional topical therapies, potentially...
In the phase 3 TRuE-AD4 trial,...
10/08/2026
First Report Managed Care
News
Service Utilization in Full-Risk Contracts May Inform Physician Fee Schedule Reform
10/07/2026
Rebecca Amrick
Researchers found that full-risk contracts were associated with variations in service utilization patterns, providing potential benchmarks which could help inform physician fee schedule reforms.
Researchers found that full-risk contracts were associated with variations in service utilization patterns, providing potential benchmarks which could help inform physician fee schedule reforms.
Researchers found that full-risk...
10/07/2026
First Report Managed Care
Behind the Bill
CMS Finalizes GLOBE Model Linking Medicare Part B Drug Rebates to International Prices
10/02/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, linking certain Medicare Part B drug rebates to international prices in an effort to lower federal spending and...
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, linking certain Medicare Part B drug rebates to international prices in an effort to lower federal spending and...
The Centers for Medicare &...
10/02/2026
First Report Managed Care
News
Coding and Favorable Selection Associated With Increased MA Rebates
10/01/2026
Rebecca Amrick
Researchers found that calculating Medicare Advantage (MA) rebates based on spending reductions alone resulted in lower monthly payments than what was observed, implying that additional factors such as coding and favorable selection might...
Researchers found that calculating Medicare Advantage (MA) rebates based on spending reductions alone resulted in lower monthly payments than what was observed, implying that additional factors such as coding and favorable selection might...
Researchers found that...
10/01/2026
First Report Managed Care

Insights

Fenty
Videos
Exploring the Impact of Early CGRP Therapy Initiation on Migraine Treatment
02/10/2025
In an interview with a guest expert, learn about the history and current use of CGRP therapies for patients with migraines.
In an interview with a guest expert, learn about the history and current use of CGRP therapies for patients with migraines.
In an interview with a guest...
02/10/2025
First Report Managed Care
LMW
Podcasts
Understanding Early CGRP Therapy Initiation in Migraine Treatment
11/22/2024
Lucy Myint-Wilks, BMBS, MSc, MRCS
Explore the latest advancements in migraine research, treatment options, cost-effectiveness, and the role of technology in managing migraines in this informative episode.
Explore the latest advancements in migraine research, treatment options, cost-effectiveness, and the role of technology in managing migraines in this informative episode.
Explore the latest advancements...
11/22/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Headshot of Ed Pezalla, Enlightenment Bioconsult, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
What Payers Should Know About Managing Chronic vs Episodic Migraine Costs
12/05/2022
Maria Asimopoulos
Edmund Pezalla, MD, MPH, chief executive officer, Enlightenment Bioconsult, LLC, reviews the costs associated with chronic vs episodic migraine and what payers should keep top of mind when managing these patients.
Edmund Pezalla, MD, MPH, chief executive officer, Enlightenment Bioconsult, LLC, reviews the costs associated with chronic vs episodic migraine and what payers should keep top of mind when managing these patients.
Edmund Pezalla, MD, MPH, chief...
12/05/2022
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
The Evolving Alzheimer Disease Treatment Landscape: Anti-Amyloid Therapies and Beyond
07/21/2026
Roy Moore
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving Alzheimer's disease pipeline, highlighting the promise of anti-amyloid therapies, emerging competitors, and the challenges ahead.
Roy Moore explores the evolving...
07/21/2026
First Report Managed Care
PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care

Subscribe to receive the latest updates in managed care!

First Report Managed Care Newsletter

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use